ProKidney Corp. - Class A Ordinary Shares

Share · KYG7S53R1049 · PROK (XNAS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of ProKidney Corp. - Class A Ordinary Shares

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

29.04.2026 19:08

Current Prices from ProKidney Corp. - Class A Ordinary Shares

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
IEX	PROK	USD	29.04.2026 19:08	1,82 USD	-0,02 USD -0,82 %
NASDAQ	PROK	USD	29.04.2026 18:53	1,82 USD	-0,01 USD -0,55 %

Share Float & Liquidity

Free Float 73,43 %

Shares Float 93,67 M

Shares Outstanding 127,57 M

Company Profile for ProKidney Corp. - Class A Ordinary Shares Share

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.